Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S13-S14, June 2016

Vaccination with Wilms' Tumor Antigen (WT1) mRNA-Electroporated Dendritic Cells as an Adjuvant Treatment in 60 Cancer Patients: Report of Clinical Effects and Increased Survival in Acute Myeloid Leukemia, Metastatic Breast Cancer, Glioblastoma and Mesothelioma

      We have previously reported the clinical and immunological effects of vaccination with dendritic cells electroporated with WT1 mRNA (WT1/DC) in 10 patients with acute myeloid leukemia (AML) (Van Tendeloo et al. PNAS 2010). In the present study, we expanded on the initial results and investigated WT1/DC as an adjuvant treatment in 60 high-risk cancer patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect